ABSTRACT Introduction: Surgery is the only potentially curative treatment for patients with colorectal liver metastases, resulting in 5-year survival rates of 36-58%. Although many studies have been performed to determine prognostic factors for tumor recurrence and survival after resection of colorectal liver metastases, there are few prognostic scoring systems stratifying patients undergoing surgery for colorectal liver metastases into risk group models. Objectives: To identify, evaluate and compare the existing prognostic scores for survival after surgery for resection of colorectal liver metastases.
BACKGROUND
Colorectal cancer (CRC) is the third most common tumor in men and the second in women, accounting for 10% of all tumor types worldwide. 1 An increasing incidence of CRC has been observed in countries where the overall risk of large bowel cancer was low, while in historically highrisk countries either a decrease (USA, Canada and New Zealand) or stabilization (Western Europe and Australia) has been reported.
1,2
In Europe, colorectal cancer (CRC) is the third most frequent cancer in the 27 countries of the European Union (EU), after breast and prostate, accounting for 13% of all cancer and is the second most frequent cause of death after Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com lung cancer. 3, 4 In 2012, new cancer cases in Europe were estimated to be 342137 (almost 1000 patients per day), comprising 191620 males (56%) and 150514 females (44%). The proportion of rectal cancer cases is variable depending on the cancer registry and classification of recto-sigmoid tumors, ranging from 27% to 58%.
3,5
The estimated number of deaths caused by CRC was 149984, comprising 53% males and 47% females. 3, 4 A considerable variation among different EU countries has been observed. The highest incidence of CRC among males is observed in central European countries compared to very low rates in Greece and Cyprus. Among females, the EU countries with the highest incidence are Denmark and the Netherlands and the lowest incidence in Greece and Finland. Concerning mortality, the variability among countries is lower than variability in incidence, probably related to differences in stage of presentation and management strategies between countries.
3
A gradient of increasing incidence and mortality due to CRC between North Western and South Eastern Europe has been observed. The growing incidence of CRC in historically low-risk areas, such as Spain and Eastern Europe reflects modifications in lifestyle behaviors and their consequences such as obesity, high red meat consumption, heavy alcohol consumption, smoking and physical inactivity. In Europe, since the 1980s, survival has markedly improved. From 1980 From until 2000 From -2002 , five-year survival for all patients increased from 51% to 60% in northern Europe; from 52% to 62% in western European and from 45% to 58% in southern European registries.
The relative increase in survival was 2% higher among females than among males across all registries. In general, improvement in survival was lower among patients with 75 years or older. 3 Concerning stage at diagnosis, almost no progress in survival was observed among patients diagnosed with metastatic disease, while a markedly improvement in survival was observed among patients diagnosed in local or regional disease. 3, 5 CRC screening has been shown to be effective in reducing mortality of the population aged 55-74 years and possibly incidence as well. A Cochrane review showed a relative reduction of 16% in the risk of CRC death using fecal occult blood tests (FOBT) every 2 years. 3, 6 Over the last few years, randomized trials have shown convincing evidence of the efficacy of flexible sigmoidoscopy in reducing the incidence and mortality from CRC. 3, 7, 8 Decrease in mortality can be attributed, not only to CRC screening 9, 10 with consequent removal of adenomas, early detection of pre-cancerous and cancerous lesions, as well as the availability of more effective therapies, mainly for early stage disease.
1
Surgical resection is the most effective therapy for metastatic colorectal cancer limited to the liver. Several studies from major centers have demonstrated that resection of as much as 80% of the liver can be performed with an associated surgical mortality rate uniformly less than 5%. [11] [12] [13] [14] [15] [16] [17] Surgery is the only potentially curative treatment for patients with colorectal liver metastases (CRLM), with studies suggesting an overall 5-year survival rate of 36-58% in contemporary series. [18] [19] [20] [21] [22] [23] [24] [25] Many studies have been performed to determine prognostic factors for tumor recurrence and survival after liver resection of CRLM. Nevertheless, only a few studies have presented prognostic scoring systems stratifying patients with CRLM submitted to surgery into risk group models which allow optimal clinical management of each patient.
OBJECTIVES
The aim of this review is to identify, evaluate and compare the existing prognostic scores that evaluate prognostic factors involved in the patient's outcome after liver resection for colorectal liver metastasis.
MATERIAL AND METHODS
An electronic search initially using the PubMed database, and later complemented by Cochrane and Embase databases was performed using the terms ('prognostic' OR 'prognosis') AND ('factors' OR 'factor' OR 'score' OR 'model') AND ('CRC' OR 'colorectal') AND ('metastasis' OR 'metastatic') AND ('liver resection' OR 'hepatic resection' OR 'hepatectomy').
Were found 1 706 articles. Articles published before 1990 (128) were excluded. After analyzing the study abstracts, 194 articles concerning animal studies were excluded. Articles written in other languages than English, French, Spanish and Portuguese were excluded (n = 230). All case reports were also excluded (n = 205). The selection of the articles was performed by the first author of this study.
From the remaining 949 studies, all studies considered irrelevant for the subject or those analyzing prognostic factors (after resection of CRLM) but not presenting a scoring system, or including patients with unresectable disease were also excluded (n = 921). From the selected studies both abstracts and full text were analyzed.
One study 26 that compared 2 clinical risks scores and TNM score, but did not present a new model, was also excluded. Studies that presented an external validation of prognostic scores were also excluded (n = 6). One study 27 performed an external validation of 5 different prognostic models with the same population.
Two studies presented scoring systems as part of the analyzed prognostic factors, namely Glasgow Prognostic Score (GPS) 28 and modified Glasgow Prognostic Score (mGPS). 29 These 2 scores took into account the elevation of c-reactive protein (CRP of > 10 mg/L) and hypoalbuminemia (< 35 g/L). However, as these studies evaluated both GPS and mGPS as one of the studied variables, and did not present a newer prognostic score, they were not included in the present study.
Finally, 19 different studies that presented a prognostic model or risk stratification based on clinical, laboratorial and/or pathological variables were included in this study. (Fig. 1) The selected articles were analysed (both abstract and full text article). Extracted and analysed data were: year of the study, authors and corresponding centre, number of patients included in each study, number of centres included, period of the study (years), median follow-up of patients (months), endpoint of the study, total number of prognostic factors tested, number and type of independent prognostic factors included in each prognostic score, risk groups evaluated in each prognostic score, 5-years overall survival after resection and type of validation of the score (internal/ external).
Data were analysed using Excel 2010™ and STATA™.
RESULTS
Several studies have correlated demographic, clinical and pathological factors with survival after hepatectomy in patients with CRLM. However, there are few studies that have presented prognostic scoring systems. To our knowledge only 2 review articles about scoring systems have been published analyzing a fewer number of scoring systems. 30, 31 Between January 1996 and June 2013, we identified 19 scoring systems, including 1 nomogram developed by Kattan et al, 32 concerning factors that influence survival after surgery of CRLM. (Table 1) Seven scoring systems were proposed from European institutions (UK = 3, France = 2, Italy = 1, Germany = 1), 6 from Asian (Japan = 5, South Korea = 1) and 6 from North American institutions (USA = 6) centers. The median study sample size was 305 patients (range 81-1568 patients) and the median follow-up was 33 months (range 16-54 months). All studies were retrospective in nature and the numbers of groups proposed by the various scoring systems ranged from three to six. All studies used the Cox proportional hazards model for multi-variable analysis.
All prognostic scoring systems were analyzed and prognostic factors, as well as risk group categories included in each model are described in Table 2 .
Prognostic factors
From the 18 prognostic scores and one nomogram presented, 30 factors that independently influenced prognosis factors after surgery of CRLM were identified ( Table 3) .
The most cited factor was the number of liver metastases, identified by 15 different studies 11, 20, [32] [33] [34] [35] [36] [37] 39, 40, [42] [43] [44] 46 ,47 as a negative prognostic factor. Only four studies 38, 41, 45, 48 did not present it as a negative prognostic factor of survival after resection of CRLM.
Twelve studies referred lymph node positivity for the primary tumor as a negative prognostic factor. 11, 20, 32, 33, [35] [36] [37] 39, 42, [44] [45] [46] Nevertheless, six studies 34, 38, 40, 41, 47, 48 concluded that regional lymph node metastases of primary tumor was not a significant prognostic factor for survival. This fact was supported by other studies not included in the analysis. [50] [51] [52] [53] [54] [55] Thus, the prognostic value of lymph node spread of primary tumor remains controversial.
Preoperative elevation of CEA was pointed in nine studies as a negative prognostic factor. 11, 20, 32, 39, [42] [43] [44] 47, 48 However, different studies used different cut-offs ranging from five 42 to 200 ng/mL. 11, 43, 48 Nine studies concluded that preoperative elevation of CEA is not significant as a prognostic factor after resection of CRLM. 33, [35] [36] [37] 40, 41, 45 Maximum size of hepatic metastases was indicated as a prognostic factor in eight studies 11, 20, 32, 33, 34, 37, 41, 46 and was considered without importance in 8 other studies. 35, 36, [38] [39] [40] [42] [43] [44] [45] 47, 48 Extrahepatic disease (EHD) was considered a poor prognostic factor in seven of the nine prognostic scores that evaluated this parameter. 11, 20, 34, 37, [46] [47] [48] In the majority of the analyzed studies patients with EHD were excluded from the analysis as many authors consider EHD a negative prognostic factor being considered as a contraindication for surgery of liver metastases in many institutions. Recently, studies have shown the contrary 56, 57 ; that isolated lung metastases when surgically resectable are no longer a contraindication for surgery and long-term survival can be archived with complete resection. 31, 47, 57 Adam et al, 47 developed a prognostic score for patients with resected CRLM and concomitant extrahepatic disease (EHD) submitted to surgery and concluded that the five negative prognostic factors for survival of this group of patients were: EHD-location other than lung metastases, EHD concomitant to CRLM recurrence, CEA ≥ 10 ng/mL, ≥ 6 liver metastases, and right colon cancer. Therefore, patients with CRLM with metachronous diagnosis of EHD, with < 6 liver metastases at diagnosis, presenting with isolated lung metastases and a CEA level < 10 ng/mL, and in whom the primary tumor is not located in the right colon, had a good long-term survival after complete resection of disease, and were considered optimal candidates for this treatment strategy. Taking into account that surgery of all resectable disease is the best chance of long-term survival, whenever technically possible, surgery should be discussed. However, in an external validation of the referred prognostic model made by Mavros et al, 25 none of these factors reached statistical significance, and only EHD other than isolated lung metastases was found to independently predict overall survival.
As for EHD, the presence of positive margins has also been considered, by many authors, as a poor prognostic factor being excluded from analysis in the majority of studies. In only six studies, positive margins were analyzed, being considered as a poor prognostic factor in three 11, 20, 34 of the six studies. In 2010, Poultsides GA et al 60 published a revision article about the impact of the surgical margin on the outcome after hepatic resection of colorectal metastases. The authors evaluated multiple studies that have specifically examined the role of a microscopically positive margin on overall survival and reported that, with the exception of one recent report, 61 all previous studies 11, [62] [63] [64] [65] [66] have demonstrated consistently that a microscopically positive R1 margin is strongly correlated with worse overall survival. Concerning the optimal size of surgical margin, Poultsides GA et al 62 concluded that, although an R1 resection should clearly be avoided, the actual margin width of an R0 resection does not impact on outcome after resection of CRLM. As such, failure to comply with the 1 cm rule can no longer be considered a contraindication for the surgical resection of CRLM.
There is a wide range in the cut-off interval of time between surgery for primary tumor and diagnosis of hepatic metastases ranging from 12 11,35 to 30 months. 34 Six studies 11, 32, 33, 34, 35, 41 considered the interval between the surgery for the primary colorectal tumor and the diagnosis of liver metastases as a prognostic factor, and six other studies 37, 40, 43, 44, 47, 48 did not find statistically relevance of this factor.
Bilobar spread was considered a poor prognostic factor in only three studies, 32, 34, 38 while in 11 other studies it was considered without importance. 11, 20, 33, 35, 37, 39, 41, [43] [44] [45] 47 Poor differentiation of primary tumor was considered a negative prognostic variable in only three studies 20, 38, 45 while in four other studies 34, 35, 39, 44 it was not significantly associated with outcome.
Two studies 33, 37 suggested that serosal invasion of primary tumor was a negative prognostic factor while two others studies did not find any difference. 35, 38 Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com The prognostic relevance of hepatic lymph node metastases was only evaluated in two studies, 41, 44 and both suggested a negative prognostic value.
Age of 60 years or more was referred by Nordlinger et al 33 as a negative prognostic factor. Age was also included in the nomogram developed by Kattan et al. 32 Some factors have been pointed as negative prognostic factors in only one prognostic score: marked tumour budding (defined as micro-tubular cancer nests or microscopic clusters of undifferentiated cancer cells) was presented by Ueno et al, 35 short doubling time of the liver tumor and marked vascular invasion were identified only in the study by Tanaka et al. 38 Synchronous liver metastases was identified as a negative prognostic factor for survival by Konopke et al. 43 More than 30% of liver invasion and non-anatomical resection were only referred by Lise et al, 36 and surgical margin ≤ 5 mm by Lee et al, 42 (lobectomy or more) was included on the nomogram by Kattan et al.
32
Other negative prognostic factors included on the evaluated scoring systems were: serum concentration of alkaline phosphatase and albumin, referred by Schindl et al, 39 GPT levels ≥ 55 U/l referred by Lise et al, 36 inflammatory response (defined by an elevated C-reactive protein (> 10 mg/L) or a neutrophil/lymphocyte ratio of > 5:1), stated by Malik et al, 40 and necessity of blood transfusion pointed by Zakaria et al. 41 Right colon as the primary colorectal location and diagnosis of extrahepatic disease concomitant to CRLM recurrence were identified by Adam et al 47 as poor prognostic factors in patients with extrahepatic disease undergoing resection of CRLM. However, as previously stated, in an external validation of the referred prognostic model made by Mavros et al, 25 none of these factors reached statistically significance, and only EHD other than isolated lung metastases was found to independently predict overall survival. The unique prognostic score that proposed the pattern of recurrence as a poor prognostic factor for survival after recurrence was developed by Hill et al. 48 Gender and primary cancer site (colon versus rectum) were also included in the nomogram developed by Kattan et al.
None of the studies included chemotherapy as a prognostic factor because of its failure to achieve statistical significance. Nevertheless, Konopke et al 43 pointed that, in the subgroup of high-risk patients, neoadjuvant chemotherapy improved the survival of the patients who underwent both chemotherapy and resection compared with those who underwent resection only. In the future, prognostic scores could be useful in selecting patients who would benefit from neoadjuvant or adjuvant chemotherapy. Currently, the only nomogram for predicting diseasesurvival after segmental hepatic resection for CRLM, was developed by Kattan et al 32 following analyses of all patients admitted to Memorial Sloan-Kettering Cancer Center (MSKCC) for curative intent for treatment of metastatic disease from CRC between 1986 and 1999. A nomogram was developed as a graphical representation of a Cox proportional hazards regression model, using as prognostic factors: nodal status of the primary tumor, disease-free interval, size of the largest metastatic tumor, preoperative CEA, bilateral resection, extensive resection (lobectomy or more), gender, number of hepatic tumors, primary cancer site (colon vs rectum), and age. The advantage of the nomogram is that, rather than counting risk factors, it takes the specific value for each factor into consideration. For example, instead of considering a preoperative CEA value above 200 to be a risk factor, the nomogram considers the patient's actual CEA value, and calculates risk accordingly, being more specific to the individual patient and thus predicting more accurately. In order to compare the prediction ability of the nomogram, Kattan et al 32 applied the clinical risk score (CRS) developed by Fong et al.
11
When refit to those patients used in the original CRS, the nomogram predicted more accurately than did the Fong score when applied to the same validation set. (0.602) than for the Fong colorectal risk score (CRS; 0.533). Therefore, the CRLM nomogram was validated by an external cohort and more accurately predicted postresection survival than the commonly used CRS.
Endpoints
Not all studies had overall survival (OS) as the endpoint. Some studies had disease-free survival (DFS) 11, 36, 42 as endpoint and some had both OS and DFS 34, 38, 40, 43, 47 Hill et al 48 had as endpoints DFS and survival after recurrence while Kattan et al 32 and Rees et al 20 had disease specific survival (DSS).
Validation of models
Before prognostic scores can be widely implemented, it is very important their validation. The validation of a model can be internal or external. The majority of the prognostic scores was not validated.
The models developed by Nordlinger et al, 33 Rees et al 20 and Konopke et al 43 underwent internal validation while models presented by Nagashima et al, 37 Schindl et al 39 The model presented by Adam et al 47 was externally validated by Mavros et al. 25 However the authors concluded that of the 5 proposed risk factors, only EHD other than isolated lung metastases was found to independently predict overall survival. A study presented by Reissfelder et al 27 performed an external validation with 281 patients of 5 different prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases: Nordlinger score, 33 MSKCC score, 11 Iwatsuki score, 34 Basingstoke index, (Rees et al) 20 and Mayo scoring system (Zacaria et al). 41 They concluded that only MSKCC score 11 (p = 0.006) and the Iwatsuki score 34 (p = 0.01) provided a statistically significant stratification of patients with regard to survival.
DISCUSSION

Limitations of the prognostic scoring systems
The ideal prognostic score has not yet been defined. All prognostic scores presented have some limitations.
All the studies proposing prognostic scores were retrospective studies. Some studies reported patients submitted to surgery in 1970 and 1980 decades. Since then, much progress has been achieved, not only in surgical techniques, but also, in the anesthesia and pre and post-operative care. Due to this progress, surgical related morbidity and mortality has been decreased in the last decades.
Selection of variables has changed a lot between different prognostic scores. While some variables were pointed as negative factors in many studies (number of liver metastases, node positive primary, preoperative CEA level, maximum size of metastases), some variables have been reported in only one prognostic score. Thus, the identification of the ideal scoring system remains controversial.
Another important aspect not correctly evaluated by these prognostic scoring systems is the importance of neoadjuvant and adjuvant chemotherapy. In the last 2 or 3 decades many agents have been approved and showed increase survival not only in the adjuvant, but also in the metastatic setting in the colorectal cancer treatment.
The median sample size is 305 patients, ranging from 81 to 1568 patients. Studies with smaller population may have greater risk of bias compared to studies including larger sample sizes.
As referred, the fact that almost all prognostic scoring systems had excluded extrahepatic disease and positive surgical margins of primary tumor, is another important limitation of the analysis because it is not possible to compare strictly different populations.
Another limitation was the fact that different studies had different endpoints, OS, DFS or DSS; and the limited number of studies that were validated. As referred in the results section, only few models were validated.
Thus, an important heterogeneity between studies has been observed, regarding studied population, exclusion criteria, quality of methodology, evaluated prognostic factors, time of follow-up, endpoints, among others.
Clinical application of scoring systems
According to current guidelines, patients with colorectal liver metastases suitable for surgery should be offered surgery in order to resect all macroscopic disease with negative margins, leaving sufficient liver remnant. Surgery of CRLM is the only chance for cure and long-time survival of these patients. 25, 47 Thus, we have to be very cautious with the clinical application of these models, especially when deciding whether to perform surgery of resectable liver metastases of colorectal cancer.
Another important value of these scoring systems is the selection of the patients that can benefit from pre-operative or subsequent chemotherapy associated or not with a biological agent. The scoring system involving prognostic factors may influence the choice of the chemotherapy regimen, especially nowadays, when a lot of different and some recent agents both cytotoxic and target agents are available for the management of metastatic colorectal disease.
CONCLUSION
After an extended research on PubMed, Cochrane and Embase databases, only 19 prognostic models of clinical outcome of patients submitted to liver resection of colorectal liver metastasis were included in this revision.
Several factors have been constantly reported as having prognostic value after liver resection of CRLM. However, none of the evaluated factors were presented in all risk models. Although some models have been externally validated, there is yet no consensus on the ideal scoring system for the approach of patients with colorectal liver metastases suitable for surgery. Although the absence of consensus of the ideal scoring system, the nomogram developed by Kattan et al 32 is undoubtedly a very practical and useful scoring system and should probably be considered when evaluating prognostic factors after liver resection for colorectal liver metastasis.
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